Post by arfanho7 on Feb 25, 2024 1:01:14 GMT -5
GenapSys device named GENIUS could also quickly generate large amounts of data as it was capable of sequencing an entire human genome in less than eight hours. At this price GenapSys device would be attractive to customers that had been unable to afford sequencers such as smaller laboratories or hospitals and even expand the market to include industries such as agriculture and biofuels.
As GenapSys came closer to releasing its product Esfandyarpour and his Senior Director of Operations and Strategy Leila Rastegar HBS sat down to decide which of three business Ukraine Mobile Number List models they would choose to bring this device to market. would sell sequencers at a higher price to those entities that already purchased sequencers primarily major research labs and pharmaceutical firms but position its machine as a faster alternative to existing technologies.
In the second model GenapSys would sell its sequencer at a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost but use the data customers generated to create a proprietary database of genetic information. Customers could pay to access the database for research to create genetic tests or for many other purposes.
As GenapSys came closer to releasing its product Esfandyarpour and his Senior Director of Operations and Strategy Leila Rastegar HBS sat down to decide which of three business Ukraine Mobile Number List models they would choose to bring this device to market. would sell sequencers at a higher price to those entities that already purchased sequencers primarily major research labs and pharmaceutical firms but position its machine as a faster alternative to existing technologies.
In the second model GenapSys would sell its sequencer at a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost but use the data customers generated to create a proprietary database of genetic information. Customers could pay to access the database for research to create genetic tests or for many other purposes.